Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that ...
With an expiration date still more than a year away, here's what the latest details reveal.
The FDA approved external trigeminal nerve stimulation (TNS) in 2019 as the first non-drug device for treating ADHD, ...
MedPage Today on MSN
Study questions benefit of FDA-cleared device for ADHD
The agency is currently reviewing the study findings ...
Study Finds on MSN
FDA-cleared brain stimulation device for ADHD works no better than placebo in major trial
In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...
A larger trial of trigeminal nerve stimulation in children with ADHD produce results that differ from an earlier pilot study, raising new questions about its efficacy.
A commonly used ADHD medication is being recalled nationwide after failing lab tests. The medication, lisdexamfetamine dimesylate capsules, is the generic form of Vyvanse, a stimulant that improves ...
News Medical on MSN
FDA-cleared ADHD device not effective in reducing symptoms
A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...
Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results